ÂÜÀòÂÒÂ×

Helen Kuhlman is an experienced professional in the pharmaceutical and biotechnology sectors, currently serving as Chief Business Officer at Evgen Pharma since April 2021. Additionally, Helen holds positions as an Operating Advisor at SymBiosis and an Independent Board Member on the Bath University Commercialisation Executive Board from December 2023. Previous roles include Senior Investment Executive at the Development Bank of Wales, VP of Corporate Development at Chronos Therapeutics, and various leadership roles at Innovate UK and the Technology Strategy Board. Helen's early career includes positions at the South West of England Regional Development Agency, SemBiosys Genetics, and Domantis. Academically, Helen obtained a PhD in Cell Physiology & Pharmacology from the University of Leicester and a BSc in Biomedical Science from the University of Portsmouth.